Candel Therapeutics
CADL
20 hedge funds and large institutions have $5.97M invested in Candel Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
1% more capital invested
Capital invested by funds: $5.92M → $5.97M (+$53K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.85% less ownership
Funds ownership: 13.93% → 13.07% (-0.85%)
9% less funds holding
Funds holding: 22 → 20 (-2)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$172K |
| 2 |
Renaissance Technologies
New York
|
+$56.8K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$49.7K |
| 4 |
TIA
Traphagen Investment Advisors
Oradell,
New Jersey
|
+$25.6K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$439K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$74.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$24.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$24.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.7K |
CADL Hedge Fund Activity: Q1 2024 in Review
20 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q1 2024, worth a combined $5.97M — up 0.9% from $5.92M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CADL and 4 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $172K. The largest seller was Fidelity Investments, exiting entirely with an estimated $439K sold.
- 20 institutional investors held Candel Therapeutics (CADL) as of Q1 2024, down from 22 in Q4 2023.
- Funds reported $5.97M of Candel Therapeutics stock for Q1 2024, up 0.9% quarter-over-quarter.
- 4 funds opened new Candel Therapeutics positions in Q1 2024 and 5 closed out, a net change of -1 holder.
- The largest Candel Therapeutics buyer in Q1 2024 was Vanguard Group, an estimated $172K added.
- The largest Candel Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $439K sold.
Based on aggregated 13F filings for Q1 2024.